⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2019MedChemComm

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Christopher W. Murray David R. Newell Patrick Angibaud

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

The winners of the Malcolm Campbell Memorial Prize for 2019 discuss the discovery of erdafitinib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Murray et al. (2019) studied this question.

synapsesocial.com/papers/6aae22302658d3a6f4ad043c https://doi.org/10.1039/c9md90044f

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaOriginal Research · 2019 · 1,367 citations
2Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer ModelsOriginal Research · 2011 · 33 citations
3Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family InhibitorOriginal Research · 2017 · 334 citations
4Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsEarly-Phase Clinical Trial · 2015 · 388 citations
5Synthesis, conformational preferences, and biological activity of conformational analogues of the microtubule-stabilizing agents, (−)-zampanolide and (−)-dactylolideMedChemComm · 2019

Selective in vitro anti-cancer activity of non-alkylating minor groove bindersMedChemComm · 2019
Recent insights into natural product inhibitors of matrix metalloproteinasesMedChemComm · 2019
Developing degraders: principles and perspectives on design and chemical spaceMedChemComm · 2019
The global antibiotic research and development partnership (GARDP): researching and developing new antibiotics to meet global public health needsMedChemComm · 2019
Isatin and its derivatives: a survey of recent syntheses, reactions, and applicationsMedChemComm · 2019

More from MedChemComm

More from Newcastle University

More from Janssen (Switzerland)

More from Newcastle College

More from Astex Pharmaceuticals

More from Northern Cancer Institute